Casi Pharmaceuticals Inc

Company Overview

Business Model: CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products globally, with a primary focus on China. The company's strategy involves acquiring, developing, and commercializing products, particularly in hematology oncology, autoimmune, and organ transplant rejection therapeutic areas, as well as other unmet medical needs. It employs a market-oriented approach to identify pharmaceutical/biotechnology candidates with potential for widespread market acceptance, leveraging its China-based regulatory, clinical, and commercial competencies and global drug development expertise. The pipeline is designed to be diversified and risk-balanced, including late-stage clinical drug candidates in-licensed for China or global regional rights, proprietary or licensed innovative drug candidates, and high-quality pharmaceuticals aligned with its therapeutic focus. The company prioritizes US/EU approved product candidates and those with proven targets or reduced clinical risk, emphasizing innovative therapeutics.

Market Position: CASI Pharmaceuticals, Inc. aims to be a biopharmaceutical leader in the greater China market. Its commercial products include EVOMELA (Melphalan for Injection), approved in China for conditioning treatment prior to stem cell transplantation and palliative treatment for multiple myeloma, and FOLOTYN (Pralatrexate), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL) and approved by both the FDA and China's NMPA. The company's partner, Juventas Cell Therapy Ltd., received NMPA market approval for CNCT19 (Inaticabtagene Autoleucel), the first CD19-directed CAR-T product with Chinese independent intellectual property rights and the first commercialized cell therapy for B-ALL in China. Additionally, CASI Pharmaceuticals, Inc. distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody, which has received NMPA approval for relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer, and was included in the National Reimbursement Drug List in December 2024. The company operates in an intensely competitive industry characterized by rapid technological evolution and significant resources from competitors. EVOMELA faces direct competition from domestically produced injectable melphalan products (Xi’An Libang Pharmaceuticals Co., Ltd. since Sept 2022, Sichuan Huiyu Pharmaceutical Co., Ltd. since March 2025). FOLOTYN competes with NRDL-listed treatments like Chidamide, Liposomal Mitoxantrone, and Golidocitinib. CID-103 faces competition from Biogen (Felzartamab), Takeda (Mezagitamab), Keymed Biosciences, and Timberlyne Therapeutics (CM313).

Recent Strategic Developments:

• Proposed Transaction: On June 21, 2024, the board received a preliminary non-binding proposal from Dr. Wei-Wu He, Chairman and CEO, to acquire the company's entire China business operations and all license-in, distribution, and related rights in Asia (excluding Japan) for pipeline products for $40.0 million (including assumption of up to $20.0 million indebtedness). A Special Committee was formed on June 25, 2024, to evaluate this and other strategic alternatives; no decisions have been made as of the filing date.
• Product Commercialization & Licensing:
  • EVOMELA: On December 13, 2024, received a Termination Process Letter from Acrotech Biopharma Inc. regarding the EVOMELA license agreement, alleging material breach. The company rejects the termination and expects a 24-month wind-down period. Acrotech Biopharma Inc. filed a complaint on March 4, 2025, seeking declaratory judgment and injunction.
  • FOLOTYN: In July 2023, entered a tripartite assignment agreement to acquire commercialization rights in China from Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc.
  • CNCT19: In November 2023, Juventas Cell Therapy Ltd. received NMPA market approval for CNCT19. On March 2, 2024, Juventas Cell Therapy Ltd. purported to terminate the CNCT19 Agreements, leading to arbitration proceedings initiated by CASI Pharmaceuticals, Inc. at the Hong Kong International Arbitration Centre on March 20, 2024. A tribunal order on February 3, 2025, allows Juventas Cell Therapy Ltd. to commercialize CNCT19 under conditions, while CASI Pharmaceuticals, Inc. retains marketing rights. PRC courts have frozen assets of both parties.
  • YuTuo (Zimberelimab): In January 2025, entered a distribution agreement with Guangzhou Gloria Biosciences Co., Ltd. for sales in China.
• Pipeline Development:
  • CID-103: In May 2024, US FDA cleared IND application for a Phase 1/2 study in adults with immune thrombocytopenia (ITP). In October 2024, China Center for Drug Evaluation approved the Clinical Trial Application for a Phase 1/2 study in chronic ITP. In January 2025, the first patient was enrolled and dosed in the ITP trial. In June 2024, China Center for Drug Evaluation approved an IND for the relapsed/refractory multiple myeloma indication. Progress is being made to lift the clinical hold for the IND application for renal allograft Antibody-Mediated Rejection in the US.
  • CB-5339: In July 2023, obtained global intellectual property rights related to CB-5339 from Cleave Therapeutics, Inc.
• Manufacturing & Capital Structure:
  • CASI Wuxi: In November 2023, CASI Pharmaceuticals (Wuxi) Co., Ltd. obtained the Drug Manufacturing Permit from local NMPA. In December 2023, entered agreements with Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) to reduce CASI Pharmaceuticals (Wuxi) Co., Ltd.'s registered capital, converting Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership)'s equity investment into a three-year long-term borrowing of RMB 134.2 million (approximately US$20 million) plus RMB 26.2 million investment return, with a 4.05% annual interest rate. CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals (China) Co., Ltd. provide guarantees.
• Financing: In July 2024, completed a private investment in public equity financing, selling 1,020,000 ordinary shares at $5.00 per share and pre-funded warrants for 1,980,000 ordinary shares at $4.9999 per share, raising $15.0 million in gross proceeds. In December 2024, filed a registration statement on Form F-3 to offer up to $200.0 million in securities, including $50.0 million via an Open Market Sale Agreement with Jefferies LLC, under which 100 ordinary shares have been sold for $257 net proceeds.

Geographic Footprint: CASI Pharmaceuticals, Inc. is a Cayman Islands holding company with the majority of its operations and activities conducted in China through its consolidated subsidiaries: CASI Pharmaceuticals (China) Co., Ltd. (headquartered in Beijing with an office in Shanghai) and CASI Pharmaceuticals (Wuxi) Co., Ltd. (located in Wuxi). The company also maintains an office in Rockville, Maryland, United States, for US business development and general administration functions. Its principal executive offices are located in Beijing, People’s Republic of China. As of December 31, 2024, the company had 233 employees, with 222 full-time employees in China, including a commercial team of 141 hematology and oncology sales and marketing specialists.

Cross-Border Operations: The company operates through a holding company structure, with its Cayman Islands parent company overseeing significant business operations conducted by its Chinese subsidiaries. In 2024, CASI Pharmaceuticals, Inc. made US$1.7 million in capital contributions to CASI Pharmaceuticals Co., Limited (Hong Kong), which currently has no meaningful operations, and paid US$19.3 million in service fees to CASI Pharmaceuticals (China) Co., Ltd. PRC foreign exchange regulations may limit the company's ability to transfer cash within its group and repatriate dividends. The company's PRC subsidiaries have obtained requisite licenses and permits, including Drug Distribution License, Drug Manufacturing Permit, Clinical Trial Applications with the NMPA, and Human Genetic Resources Agency approvals for international collaborative clinical trials. Future offerings and major changes are subject to filing procedures under China Securities Regulatory Commission's Overseas Listing Trial Measures. The company's auditor, KPMG Huazhen LLP, is located in mainland China, and while the PCAOB has recently gained full inspection access, there remains a risk of future delisting if full access is lost again for two consecutive years. The company's intellectual property strategy involves seeking patent protection in China, the United States, Canada, and other key markets, with specific licensing agreements for its product candidates across various jurisdictions. The supply chain relies on third-party suppliers and distributors, including Acrotech Biopharma Inc. for EVOMELA and FOLOTYN, BioInvent International AB for BI-1206, Esteve Healthcare, S.L. for Thiotepa, China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. for EVOMELA distribution, China National Medicines Corporation Ltd. for FOLOTYN distribution, and Guangzhou Gloria Biosciences Co., Ltd. for YuTuo (Zimberelimab) distribution in China.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 39.0% (2024), 59.3% (2023)
• Operating Margin: -138.9% (2024), -74.0% (2023)
• Net Margin: -137.9% (2024), -77.6% (2023)

Investment in Growth:

• R&D Expenditure: $8.9 million (31.2% of revenue)
• Capital Expenditures: $0.2 million
• Strategic Investments: In July 2024, CASI Pharmaceuticals (China) Co., Ltd. entered an agreement to purchase 19.8876% equity interest of Precision Autoimmune Therapeutics Co., Ltd. for RMB 28.4 million (approximately US$3.9 million) plus interest, with RMB 10.0 million (approximately US$1.4 million) paid in August 2024.

Currency Impact Analysis: The company reported a foreign exchange loss of $0.2 million in 2024, compared to a gain of $0.2 million in 2023 and $3.2 million in 2022. These fluctuations are primarily due to the exchange rate of RMB against USD, impacting accounts receivable with distributors and USD/RMB denominated cash accounts held by subsidiaries. Substantially all revenues and a major part of expenses are denominated in RMB. The conversion of RMB into foreign currencies is subject to rates set by the People’s Bank of China, which can fluctuate significantly and unpredictably. The company does not currently use derivative financial instruments to hedge foreign exchange risk. As of December 31, 2024, China subsidiaries held RMB 30.1 million (US$4.1 million) in cash and cash equivalents, representing 31% of the total. PRC foreign exchange regulations may limit the ability to utilize these cash balances effectively.

Business Segment Analysis

The company operates as a single segment focused on pharmaceutical products, specifically the development of innovative therapeutics addressing cancer and other unmet medical needs for the global market. Therefore, a detailed segment breakdown is not applicable. Below is an analysis of the company's key products and candidates.

EVOMELA (Melphalan for Injection)

Financial Performance: Revenue decreased in 2024 due to intensified competition. Direct costs of revenues as a percentage of EVOMELA sales were 41% in both 2024 and 2023. Product Portfolio: An intravenous formulation of melphalan that utilizes Captisol to enhance stability, allowing for extended preparation and infusion times. Market Dynamics: Approved in China for conditioning treatment prior to stem cell transplantation and as a palliative treatment for multiple myeloma. Faces significant competition from domestically produced injectable melphalan products, including Xi’An Libang Pharmaceuticals Co., Ltd. (propylene glycol formulation, Sept 2022) and Sichuan Huiyu Pharmaceutical Co., Ltd. (Captisol formulation, March 2025). Market access is constrained by challenges in National Reimbursement Drug List inclusion and hospital formulary listings. Geographic Revenue Distribution: Solely in mainland China.

FOLOTYN (Pralatrexate)

Financial Performance: Direct costs of revenues as a percentage of FOLOTYN sales was 76% in 2024, attributed to a relatively small market and fierce local competition. An impairment loss of $0.7 million was recognized in Q4 2024 due to lower-than-expected market conditions. Product Portfolio: A dihydrofolate reductase inhibitor. Market Dynamics: Indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Approved by both the FDA and China’s NMPA. The application for inclusion in the National Reimbursement Drug List was rejected, limiting market reach to self-pay patients. Faces competition from treatments with novel targets, including NRDL-listed Chidamide, Liposomal Mitoxantrone, and Golidocitinib. Geographic Revenue Distribution: Solely in mainland China.

CNCT19 (Inaticabtagene Autoleucel)

Financial Performance: No specific revenue figures available. Affordability and accessibility are significant barriers to widespread adoption in China, with a cost of RMB 999,000. Product Portfolio: An autologous CD19 CAR-T investigational product. Market Dynamics: Received NMPA market approval in November 2023 for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. It is the first CD19-directed CAR-T product with Chinese independent intellectual property rights and the first commercialized cell therapy for B-ALL in China. Exclusion from the National Reimbursement Drug List in the foreseeable future and slow acceptance among doctors pose considerable barriers. Juventas Cell Therapy Ltd. serves as the sole supplier and business partner, with limited manufacturing capacity. Geographic Revenue Distribution: China.

BI-1206 (anti-FcγRIIB antibody)

Financial Performance: Not applicable, in clinical development. Product Portfolio: A novel anti-FcγRIIB antibody. Market Dynamics: Exclusive licensing agreement with BioInvent International AB for development and commercialization in China, Taiwan, Hong Kong, and Macau. Currently in a Phase 1 study in China in combination with rituximab for non-Hodgkin lymphoma (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma). Key Growth Drivers: Potential for both hematological malignancies and solid tumors. Geographic Revenue Distribution: China, Taiwan, Hong Kong, Macau.

CB-5339 (VCP/p97 inhibitor)

Financial Performance: Not applicable, in clinical development. Product Portfolio: An oral second-generation, small molecule VCP/p97 inhibitor. Market Dynamics: Global intellectual property rights obtained from Cleave Therapeutics, Inc. in July 2023. CTA application for the multiple myeloma indication approved by the NMPA in January 2023. Key Growth Drivers: Targets valosin-containing protein (VCP)/p97 in protein homeostasis, DNA damage response, and other cellular stress pathways for various malignancies. Geographic Revenue Distribution: Global intellectual property rights, with initial development focus on mainland China, Hong Kong, Macau, and Taiwan.

CID-103 (anti-CD38 monoclonal antibody)

Financial Performance: Not applicable, in clinical development. Product Portfolio: A full human IgG1 anti-CD38 monoclonal antibody. Market Dynamics: Exclusive global rights. Development for multiple myeloma, organ transplant rejection (Antibody-Mediated Rejection), and autoimmune diseases (immune thrombocytopenia). INDs/CTAs approved in the US and China for ITP and relapsed/refractory multiple myeloma. Faces competition from other anti-CD38 antibodies in development for similar indications. Key Growth Drivers: Demonstrated encouraging pre-clinical efficacy and safety profile, recognizing a unique epitope. Geographic Revenue Distribution: Global rights, with active development in the US and China.

Thiotepa

Financial Performance: Not applicable, in generic registration phase. Product Portfolio: A chemotherapeutic agent. Market Dynamics: Exclusive China license and distribution rights from Riemser Pharma GmbH (now Esteve Healthcare, S.L.). The company is applying for generic registration. Key Growth Drivers: Multiple indications, including conditioning treatment for allogeneic haemopoietic stem cell transplants, with a long history of established use in hematology/oncology. Geographic Revenue Distribution: China.

YuTuo (Zimberelimab)

Financial Performance: Not applicable, recently entered distribution. Product Portfolio: The world's first fully human anti-PD-1 monoclonal antibody developed by the transgenic rat platform, OmniRat®. Market Dynamics: Distribution agreement with Guangzhou Gloria Biosciences Co., Ltd. for China. Approved in China for relapsed or refractory classical Hodgkin's lymphoma (Aug 2021) and recurrent or metastatic cervical cancer (2023, Breakthrough Therapy designation). Included in the National Reimbursement Drug List in December 2024. Geographic Revenue Distribution: China.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries:
  • CASI Pharmaceuticals (China) Co., Ltd.: Wholly owned, based in Beijing with an office in Shanghai. Responsible for day-to-day operations, commercial activities, technology transfer, local pre-clinical and clinical operations, NMPA regulatory activities, business development, and executive management.
  • CASI Pharmaceuticals (Wuxi) Co., Ltd.: 80% owned, located in Wuxi, China. Established to support future clinical and commercial manufacturing needs, manage the supply chain for certain products, and develop a GMP manufacturing facility.
  • CASI Pharmaceuticals Co., Limited: Hong Kong subsidiary with no meaningful operations.
• Joint Ventures: While CASI Pharmaceuticals (Wuxi) Co., Ltd. was initially established with Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) holding a 20% equity interest, this equity was converted into a long-term borrowing in December 2023.
• Licensing Agreements:
  • EVOMELA: Exclusive greater China rights from Acrotech Biopharma Inc. (currently under dispute regarding termination).
  • FOLOTYN: China commercialization rights assigned from Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc.
  • CNCT19: Exclusive worldwide co-commercial and profit-sharing rights from Juventas Cell Therapy Ltd. (currently under arbitration).
  • BI-1206: Exclusive licensing agreement with BioInvent International AB for mainland China, Taiwan, Hong Kong, and Macau.
  • CB-5339: Global intellectual property rights obtained from Cleave Therapeutics, Inc.
  • CID-103: Exclusive worldwide rights from Black Belt Therapeutics Limited. Sublicensed to Precision Autoimmune Therapeutics Co., Ltd. for autoimmune indications.
  • Thiotepa: Exclusive China license and distribution rights from Riemser Pharma GmbH (now Esteve Healthcare, S.L.).
  • YuTuo (Zimberelimab): Distribution agreement with Guangzhou Gloria Biosciences Co., Ltd. for China.

Cross-Border Trade:

• Export Markets: Not explicitly detailed in the filing.
• Import Dependencies: The company relies on Acrotech Biopharma Inc. as the sole supplier for EVOMELA and FOLOTYN. BI-1206 supply is expected from BioInvent International AB and its contract manufacturers. Thiotepa is supplied by Esteve Healthcare, S.L.
• Transfer Pricing: Earnings of PRC subsidiaries under service agreements are subject to a statutory tax rate of 25% under PRC tax laws. The company's international tax strategy includes transfer pricing considerations, but specific inter-company policies and documentation requirements are not detailed.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases were made in 2024. The company repurchased $0.3 million in 2023 and $3.3 million in 2022.
• Dividend Payments: The company has never declared or paid dividends on its ordinary shares and does not anticipate paying any in the foreseeable future, retaining earnings for operations and business expansion.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific future capital return commitments are disclosed.

Balance Sheet Position:

• Cash and Equivalents: $13.5 million as of December 31, 2024.
• Total Debt: $18.4 million as of December 31, 2024, consisting of the current portion of long-term borrowing.
• Net Cash Position: -$4.9 million (net debt) as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The long-term borrowing from Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) (RMB 134.2 million, approximately US$20 million) has a term from December 25, 2023, to December 31, 2026, with a non-compounding annual interest rate of 4.05%. Due to CASI Pharmaceuticals (Wuxi) Co., Ltd.'s failure to meet the revenue threshold in 2024, Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) has the right to request immediate repayment, leading to the reclassification of the entire balance to current liability. Lease obligations have future undiscounted cash flows of $1.3 million in 2025, $1.2 million in 2026, $0.9 million in 2027, $0.3 million in 2028, and $0.3 million in 2029.

Cash Flow Generation:

• Operating Cash Flow: -$29.2 million in 2024, -$20.0 million in 2023, and -$21.1 million in 2022.
• Free Cash Flow: -$29.4 million in 2024 (Operating Cash Flow - Capital Expenditures).
• Cash Conversion Metrics: Not explicitly disclosed.

Currency Management: The company's cash holdings as of December 31, 2024, include RMB 30.1 million (US$4.1 million) in mainland China, representing 31% of total cash and cash equivalents. The remaining cash is held in the US and Hong Kong. The company does not currently use derivative financial instruments for hedging foreign exchange risk.

Operational Excellence

Production & Service Model: CASI Pharmaceuticals, Inc. operates as a fully integrated biopharmaceutical company, focusing on the development and commercialization of innovative therapeutics. Its operational philosophy centers on a market-oriented approach to identify promising pharmaceutical/biotechnology candidates and accelerate their development through a global drug development strategy. The company leverages its China-based regulatory, clinical, and commercial expertise, alongside global drug development knowledge, to maximize strategies in both the U.S. and China. CASI Pharmaceuticals (Wuxi) Co., Ltd. is integral to the long-term strategy, aiming to support future clinical and commercial manufacturing needs and manage the supply chain for certain products. It operates a cGMP injectable products manufacturing line in a state-owned industrial facility in Wuxi Huishan Economic Development Zone, having obtained the Drug Manufacturing Permit in November 2023. However, this manufacturing line is not yet approved by the China Center for Drug Evaluation for commercial product manufacturing and has not been put to use.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Acrotech Biopharma Inc.: Sole supplier for EVOMELA and FOLOTYN.
• BioInvent International AB: Partner for the development and commercialization of BI-1206. Expected to supply BI-1206.
• Contract Manufacturers: Expected to supply clinical materials and commercial inventory for CID-103 and for local development of BI-1206 in China.
• Esteve Healthcare, S.L. (formerly Riemser Pharma GmbH): Responsible for manufacturing and supplying Thiotepa.
• Juventas Cell Therapy Ltd.: Partner for CNCT19, responsible for clinical development, regulatory submission and maintenance, and serves as the sole supplier.
• China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (CRPCGIT): Exclusive distributor for EVOMELA in China.
• China National Medicines Corporation Ltd. (CNMC): Exclusive distributor for FOLOTYN in China.
• Guangzhou Gloria Biosciences Co., Ltd.: Distributor for YuTuo (Zimberelimab) in China.

Facility Network:

• Manufacturing: CASI Pharmaceuticals (Wuxi) Co., Ltd. leases approximately 10,000 square meters of workshop and office space in Wuxi, China, with 60% dedicated to the production workshop.
• Research & Development: CASI Pharmaceuticals (China) Co., Ltd. oversees local pre-clinical and clinical operation activities from its Beijing headquarters and Shanghai office.
• Distribution: The company's principal executive offices in Beijing, China, and a regional office in Shanghai support commercial and administrative functions. A US office in Rockville, Maryland, handles business development and general administration. Distribution relies on third-party partners in China.

Operational Metrics: The filing does not provide specific operational metrics such as capacity utilization, efficiency measures, or quality indicators.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: The company employs an internal marketing and sales team, comprising 141 hematology and oncology specialists in China, responsible for direct interaction with therapeutic area experts, physicians, hospital centers, and sales generation for its products.
• Channel Partners:
  • China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (CRPCGIT): Serves as the exclusive distributor for EVOMELA in China, with the agreement renewed in February 2024 for an additional three years.
  • China National Medicines Corporation Ltd. (CNMC): Acts as the exclusive distributor for FOLOTYN in China, with the agreement extended until December 5, 2026.
  • Guangzhou Gloria Biosciences Co., Ltd.: Appointed as a distributor for YuTuo (Zimberelimab) in China under a three-year agreement starting January 2025.
• Digital Platforms: Not explicitly detailed in the filing.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The company's direct sales efforts target major enterprise relationships, including therapeutic area experts, physicians, and hospital centers across regions.
• Strategic Partnerships: Key partnerships include Acrotech Biopharma Inc. (for EVOMELA and FOLOTYN supply), Juventas Cell Therapy Ltd. (for CNCT19 co-commercialization), BioInvent International AB (for BI-1206 development), Cleave Therapeutics, Inc. (for CB-5339 IP), Black Belt Therapeutics Limited (for CID-103 global rights), Esteve Healthcare, S.L. (for Thiotepa supply), and Precision Autoimmune Therapeutics Co., Ltd. (for CID-103 sublicense).
• Customer Concentration: The company faces significant customer concentration risk, with CRPCGIT being the sole customer for EVOMELA sales and CNMC being the sole customer for FOLOTYN sales in China.

Regional Market Penetration:

• Mainland China: Represents 100% of the company's revenue. Market penetration for EVOMELA is constrained by challenges in National Reimbursement Drug List (NRDL) inclusion and hospital formulary access. FOLOTYN's market reach is limited due to its NRDL rejection, primarily serving a self-pay patient segment. CNCT19 faces significant barriers to widespread adoption due to its high cost (RMB 999,000), variable health insurance coverage, economic disparities, and exclusion from the NRDL. YuTuo (Zimberelimab) benefits from its inclusion in the NRDL in December 2024.
• Growth Markets: The company's strategy includes leveraging its cross-border operations and expertise to access the China market, which offers significant growth potential due to increasing demand for high-quality medicines and regulatory reforms.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by intense competition driven by scientific and technological advancements, intellectual property protection, regulatory approval timelines, and the ability to commercialize products efficiently. The industry is undergoing rapid technological change, with increasing consolidation and competition as technical advances become more widespread. The China market, in particular, is experiencing an extraordinary increase in demand for high-quality medicines, supported by regulatory reforms that facilitate the entry of new pharmaceutical products.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• EVOMELA:
  • Xi’An Libang Pharmaceuticals Co., Ltd.: Introduced the first domestically produced injectable melphalan (propylene glycol formulation) in September 2022, directly competing with EVOMELA.
  • Sichuan Huiyu Pharmaceutical Co., Ltd.: Launched the second domestically produced injectable melphalan (Captisol formulation) in March 2025, further intensifying competition.
• FOLOTYN:
  • Chidamide: Listed in the National Reimbursement Drug List (NRDL).
  • Liposomal Mitoxantrone: Listed in the NRDL.
  • Golidocitinib: Listed in the NRDL.
  • FOLOTYN, as a traditional chemotherapy, faces competition from these NRDL-listed treatments with novel targets, leading to market share erosion.
• CNCT19:
  • Other CAR-T clinical trials in China: The saturation of CAR-T clinical trials in China creates intense competition for eligible self-pay patients.
• CID-103:
  • Biogen (Felzartamab): Initiated a Phase 3 trial for late Antibody-Mediated Rejection (AMR) in kidney transplant patients and is developing it for IgA nephropathy and primary membranous nephropathy.
  • Takeda (Mezagitamab): Developing in a global Phase 3 trial for Immune Thrombocytopenia.
  • Keymed Biosciences and Timberlyne Therapeutics (CM313): Developing a monoclonal antibody targeting CD38 for treatment-refractory Immune Thrombocytopenia.

Regional Competitive Dynamics: Many existing or potential competitors possess substantially greater financial, technical, and human resources, and extensive experience in pre-clinical testing, clinical trials, and regulatory approvals. The relative speed of product development, clinical trial completion, regulatory approvals, and market commercialization are critical competitive factors.

Risk Assessment Framework

Strategic & Market Risks

• Global Market Dynamics: The company faces intense competition from other biotechnology and pharmaceutical companies, many with greater resources, which could render its products noncompetitive or obsolete. The success of its products is highly dependent on market acceptance, which can be inhibited by price competition, reimbursement issues, or physician preference for alternative treatments. The presence of counterfeit pharmaceutical products, particularly in China, poses a significant risk to brand reputation and revenues due to diversion of sales and potential adverse events.
• Regulatory Approval & Market Access: The unpredictable and lengthy process of obtaining regulatory approvals (FDA, NMPA, EMA) for drug candidates is a substantial risk. Delays in clinical trials, failure to demonstrate safety and efficacy, data integrity issues, or changes in regulatory policies could prevent or delay approval. For approved products, maintaining market acceptance is challenging due to National Reimbursement Drug List (NRDL) inclusion hurdles (e.g., FOLOTYN, CNCT19), hospital formulary restrictions, and government price negotiations that often result in significant discounts.
• Intellectual Property: The company's success relies on its ability to protect intellectual property through patents and trade secrets. However, patent positions in the biotechnology and pharmaceutical industries are highly uncertain, and third parties may challenge, invalidate, or circumvent patents. Disputes with licensing partners over IP rights could also adversely impact the business. The evolving patent laws and lack of effective regulatory exclusivity in China could lead to earlier generic or biosimilar competition.

Operational & Execution Risks

• Global Supply Chain Vulnerabilities: The company relies on single-source suppliers for key products like EVOMELA and FOLOTYN (Acrotech Biopharma Inc.), making it vulnerable to supply disruptions, increased costs, or delays if the supplier is unable to meet obligations.
• Manufacturing Capacity: CASI Pharmaceuticals (Wuxi) Co., Ltd.'s cGMP injectable products manufacturing line is not yet approved by the China Center for Drug Evaluation for commercial use, and the company has limited experience in large-scale manufacturing. Difficulties in scaling up production, quality control, or personnel shortages could delay commercialization.
• Partner Dependence: Significant dependence on partners like Juventas Cell Therapy Ltd. for clinical development, regulatory submissions, and supply of CNCT19. Ongoing arbitration proceedings with Juventas Cell Therapy Ltd. regarding purported termination of license agreements pose a risk of delays or adverse impacts on CNCT19 commercialization.
• CASI Wuxi Business Plan: The success of CASI Pharmaceuticals (Wuxi) Co., Ltd. is subject to uncertainties in its business plan and government regulatory actions. Failure to meet revenue thresholds for the long-term borrowing from Wuxi Huicheng Yuanda Investment Partnership (Limited Partnership) could trigger immediate repayment, creating a significant liquidity risk.
• Key Personnel: The company's future success is substantially dependent on its senior management and key employees. Intense competition for qualified talent in the biopharmaceutical industry in China could make it difficult to attract and retain personnel, potentially affecting growth.

Financial & Regulatory Risks

• Currency & Financial Risks: The company has incurred significant operating losses since inception, with an accumulated deficit of $700.1 million as of December 31, 2024, raising substantial doubt about its ability to continue as a going concern. It requires additional liquidity and may need to raise further equity or debt capital, with no assurance of success on favorable terms. Fluctuations in the RMB/USD exchange rate significantly impact financial results, and PRC government controls on currency conversion and remittance may limit the effective utilization of cash balances.
• Regulatory & Compliance Risks: The company is subject to extensive and evolving regulations in the U.S. (FDA, healthcare laws like AKS, False Claims Act, HIPAA, PPACA) and China (NMPA, Drug Registration Regulation, Marketing Authorization Holder System, GLP, GCP, HGR Regulation, Biosecurity Law, Company Law). Non-compliance can lead to severe sanctions, fines, withdrawal of approvals, or operational restrictions. New or changing PRC laws, including those related to data security (Cyberspace Administration of China) and overseas listings (China Securities Regulatory Commission's Overseas Listing Trial Measures), could impose additional requirements and costs.
• International Tax Strategy: If deemed a PRC tax resident enterprise, the company could be subject to a 25% enterprise income tax on its worldwide income, and dividends to non-PRC shareholders might face 10-20% withholding tax. Capital gains from share transfers by non-PRC shareholders could also be taxed in China. Compliance with SAFE regulations for China residents' offshore investments and employee share options is critical, with potential penalties for non-compliance.

Geopolitical & External Risks

• Country-Specific Risks: Substantial operations in China expose the company to risks from changes in Chinese government policies (economic, political, social, tax, trade, environmental, land use, healthcare). Governmental control over the economy and potential shifts towards a more centrally planned economy could significantly affect business conditions.
• Auditor Inspection: While the PCAOB has recently gained full inspection access to auditors in mainland China and Hong Kong, there is a risk that future loss of access for two consecutive years could lead to the delisting of the company's ordinary shares from U.S. exchanges, substantially impairing liquidity and ability to raise capital.

Innovation & Technology Leadership

Research & Development Focus: CASI Pharmaceuticals, Inc. is strategically focused on developing and commercializing innovative therapeutics in hematology oncology, autoimmune, and organ transplant rejection, as well as other areas of unmet medical need. The company's R&D efforts are guided by a market-oriented approach, prioritizing US/EU approved product candidates and those with proven targets or reduced clinical risk. In 2024, R&D expenditure was $8.9 million. Key R&D investments in 2024 included CID-103 ($3.5 million), ANDAs ($0.7 million), BI-1206 ($0.7 million), EVOMELA ($0.3 million), generic pharmaceuticals ($0.2 million), Thiotepa ($0.2 million), and CB-5339 ($0.07 million).

Global R&D Network: The company's R&D activities are primarily managed through its China subsidiaries, CASI Pharmaceuticals (China) Co., Ltd., which oversees local pre-clinical and clinical operations. The US office in Rockville, Maryland, also contributes to business development and general administration functions that support global R&D initiatives.

• Innovation Pipeline:
  • CID-103: An anti-CD38 antibody with exclusive global rights, being developed for multiple myeloma, organ transplant rejection (AMR), and autoimmune diseases (ITP), with active INDs/CTAs in the US and China.
  • BI-1206: An anti-FcγRIIB antibody, licensed for greater China, undergoing a Phase 1 study in China for non-Hodgkin lymphoma.
  • CB-5339: A VCP/p97 inhibitor, for which the company obtained global intellectual property rights, with a CTA approved in China for multiple myeloma.
  • CNCT19: A CD19 CAR-T therapy, for which the company holds worldwide co-commercial rights, has received market approval in China for r/r B-ALL.
  • Thiotepa: A chemotherapeutic agent, for which the company holds exclusive China license and distribution rights, is in the process of generic registration.

Intellectual Property Portfolio: The company actively seeks patent protection for its technology and product candidates in key markets including China, the United States, and Canada, aligning its IP strategy with its overall business objectives.

• Patent Strategy: The company holds exclusive licenses for EVOMELA (greater China) and FOLOTYN (China). For CNCT19 and BI-1206, the respective partners, Juventas Cell Therapy Ltd. and BioInvent International AB, are responsible for prosecuting and maintaining the licensed intellectual property. The company has obtained global intellectual property rights for CB-5339. For CID-103, it holds an exclusive worldwide license to patents covering the antibodies and treatment methods, with pending applications in multiple jurisdictions including the U.S., Australia, Canada, China, Europe, India, Japan, Korea, New Zealand, Singapore, and Hong Kong. The patent term for the earliest pending CID-103 applications is expected to expire in June 2038.
• Trademark Strategy: The company owns registered trademarks and has pending applications for "CASI," its corporate logo, and product names in China, the United States, and other jurisdictions.
• IP Litigation: The company is involved in arbitration proceedings with Juventas Cell Therapy Ltd. regarding the CNCT19 Agreements, highlighting the risk of disputes over license scope, ownership, and commercialization rights.

Technology Partnerships: The company engages in strategic alliances and research collaborations with various partners to advance its pipeline, including BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., Juventas Cell Therapy Ltd., Precision Autoimmune Therapeutics Co., Ltd., Guangzhou Gloria Biosciences Co., Ltd., and Esteve Healthcare, S.L.

Leadership & Governance

Executive Leadership Team

International Management Structure: Global management decisions are primarily made out of CASI Pharmaceuticals (China) Co., Ltd. in Beijing, where the executive team spends a significant amount of time. The company's structure includes regional leadership within its Chinese subsidiaries.

Board Composition: The board of directors consists of five directors. The Audit Committee comprises Thomas Folinsbee (Chairperson and financial expert), Y. Alexander Wu, Ph.D., and Xuebo Zeng. The Compensation Committee includes Y. Alexander Wu, Ph.D. (Chairperson), Xuebo Zeng, and Zhenbo Su. The Nominating and Corporate Governance Committee consists of Zhenbo Su (Chairperson), Thomas Folinsbee, and Xuebo Zeng. All members of these committees are independent directors, meeting Nasdaq listing rules and SEC criteria. The board's composition reflects international expertise and a commitment to regulatory compliance.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments:

• United States: The company's research, development, manufacturing, and commercialization activities are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. This includes rigorous processes for Investigational New Drug (IND) applications, clinical trials (Phases 1-4), New Drug Applications (NDAs) or Biologics License Applications (BLAs), and ongoing post-marketing obligations (e.g., adverse event reporting, cGMP compliance, labeling, advertising). The company is also subject to U.S. healthcare laws, including the federal Anti-Kickback Statute, False Claims Laws, Health Insurance Portability and Accountability Act (HIPAA), and the Patient Protection and Affordable Care Act (PPACA), which govern marketing practices, pricing, and data privacy.
• China (People's Republic of China): Substantially all operations are conducted in China, subject to complex and evolving PRC laws and regulations. Key regulatory bodies include the National Medical Products Administration (NMPA), which oversees pharmaceutical products, and the Human Genetic Resources Agency (under the National Health Commission) for biospecimen and data collection. The "Law of the PRC on the Administration of Pharmaceuticals" and "Drug Registration Regulation" provide the basic legal framework. The Marketing Authorization Holder System assigns lifecycle responsibility for drug products. Manufacturing requires a Drug Manufacturing Permit and compliance with NMPA Good Manufacturing Practice (GMP) guidelines. Clinical trials follow a negative notification system for approvals and adhere to China's Good Clinical Practice (GCP). The PRC Biosecurity Law and Human Genetic Resources Regulation govern the collection and use of human genetic resources. Import Drug Registration and Multi Regional Clinical Trials (IMCT) processes are streamlined for new drugs. Pricing is regulated by the government through price negotiations and centralized procurement mechanisms, impacting National Reimbursement Drug List (NRDL) inclusion and hospital formulary listings. The company is also subject to the Company Law of the PRC and foreign exchange controls by the State Administration of Foreign Exchange (SAFE) and the People’s Bank of China (PBOC).
• Hong Kong: The company's subsidiary in Hong Kong is subject to Hong Kong profits tax at a rate of 16.5%, with a two-tiered regime applying 8.25% to the first HK$2 million of assessable profits.
• Cayman Islands: As an exempted company, CASI Pharmaceuticals, Inc. is not subject to taxes on profits, income, gains, or appreciation, and there are no withholding taxes on dividend payments.

Cross-Border Compliance: The company faces compliance challenges across multiple jurisdictions, including export controls, sanctions compliance, and anti-corruption laws such as the U.S. Foreign Corrupt Practices Act (FCPA) and local anti-bribery laws in China. Compliance with these regulations requires robust internal policies and monitoring programs.

International Tax Strategy: PRC subsidiaries are subject to a 25% enterprise income tax rate on worldwide taxable income. Dividends from PRC subsidiaries to the parent company are subject to a 10% withholding tax, unless a tax treaty provides a lower rate. The company is treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code, meaning dividends paid by it may be subject to U.S. withholding taxes. The "de facto management body" test under PRC tax law creates uncertainty regarding the company's PRC tax residency status, which could impact its global income taxation and withholding taxes on dividends and capital gains for non-PRC shareholders. SAFE regulations (Circular 37 and Circular 7) require China residents to register offshore investments and employee share options, with potential penalties for non-compliance.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies: The company does not currently use any derivative financial instruments to hedge its exposure to foreign exchange risk. Its exposure to foreign exchange risk is primarily related to RMB-denominated revenues and expenses, as well as USD-denominated cash accounts held by Chinese subsidiaries and RMB-denominated cash accounts held by CASI Pharmaceuticals, Inc. (Cayman Islands). The company's China subsidiaries held RMB 30.1 million (US$4.1 million) in cash and cash equivalents as of December 31, 2024, representing 31% of its total cash. The conversion of RMB into foreign currencies is subject to controls by the People’s Bank of China and the State Administration of Foreign Exchange, which can limit the company's ability to utilize its cash balances effectively.